SMALL LYMPHOCYTIC LYMPHOMA
Clinical trials for SMALL LYMPHOCYTIC LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new SMALL LYMPHOCYTIC LYMPHOMA trials appear
Sign up with your email to follow new studies for SMALL LYMPHOCYTIC LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo tested for Tough-to-Treat cancers
Disease control CompletedThis early-phase study tested the safety and best dose of a new drug called BGB-10188. It was given alone or combined with other cancer drugs to 97 patients with advanced blood cancers or solid tumors that had returned or stopped responding to prior treatments. The main goal was …
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New drug combo aims to knock out blood cancer
Disease control CompletedThis study tested a combination of three medications—ofatumumab, methylprednisolone, and lenalidomide—for people newly diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The main goal was to see if this treatment could effectively control the c…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New drug combo tested to control blood cancer
Disease control CompletedThis study tested a combination of two drugs, idelalisib and ofatumumab, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had not yet received treatment. The goal was to see if using these drugs together was safe and effective at controll…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New pill tested for Tough-to-Treat blood cancers
Disease control CompletedThis study tested a new oral medication called pirtobrutinib for people with chronic lymphocytic leukemia or other B-cell lymphomas that had stopped responding to standard treatments. The main goals were to find a safe and effective dose and to see if the drug could shrink tumors…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Loxo Oncology, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New drug cocktail tested for Tough-to-Treat blood cancers
Disease control CompletedThis early-stage study tested the safety and initial effectiveness of combining the drug acalabrutinib with other cancer medications for patients with chronic lymphocytic leukemia (CLL) and related blood cancers. It involved 69 patients, some who had been treated before and some …
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE1 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Early trial tests re-engineered immune cells against tough blood cancers
Disease control CompletedThis early-stage study tested a new cell therapy called IOV-2001 for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma that had returned or stopped responding to standard drugs. The main goals were to find a safe dose and see if the treatment could shrink t…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE1 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
New drug targets Tough-to-Treat blood cancer
Disease control CompletedThis study tested whether the drug acalabrutinib could help control chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in people whose cancer had returned after treatment or who had a specific high-risk genetic change called 17p deletion. The trial involved 48…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated Feb 23, 2026 14:55 UTC